CDK4 and ovarian carcinoma: Another example of a gene commonly inactivated by structural variants is RB1, an important biomarker of resistance to CDK4/6 inhibitors such as palbociclib, with this class of event contributing to 47% and 43% of RB1 inactivation in breast and ovarian cancer respectively (Fig. 6).